Clinical trials: Transplants
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Adenovirus, CMV and EBV
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV or EBV in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus
- Trial name
- NCT04364178
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, EBV Specific T-Lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jessie L. Alexander, MD
Anorexia Nervosa, Microbiome Dysbiosis
Feasibility Study of Using Fecal Microbiota Transplants in Anorexia Nervosa
The investigators hypothesize that prolonged undernutrition in anorexia nervosa alters the microbiome to a different steady-state (dysbiotic) composition that sustains the disease, even after returning to normal diet.
- Trial name
- ReBoot (NCT05834010)
- Testing
- Fecal Microbiome Transplant
- Where
- 3 sites in Denmark
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Actinic Keratoses, Skin Neoplasms
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
The purpose of this study is to determine and compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) versus vehicle PDT (VEH-PDT) in the treatment of actinic keratoses (AK) and…
- Trial name
- NCT00865878
- Testing
- Aminolevulinic Acid, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Lung Transplantation
Live Lung Donor Cross-sectional Cohort Study
This study will gather information on the long-term effects of donating a lung lobe on living donors.
- Trial name
- NCT01524835
- Where
- 2 sites in United States
- Volunteers
- 192 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplantation, Ischemia-Reperfusion Injury
Thymoglobulin Induction in Kidney Transplant Recipients
The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted from deceased donors…
- Trial name
- TIKT (NCT01239563)
- Testing
- antithymocyte globulin, Basiliximab
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Zoster; Herpes
Zoster Vaccine to Enhance Protection Against Zoster in Solid-organ Transplantation
Shingles is caused by the same virus that causes chickenpox. After someone has chickenpox, the virus stays in the body and can become active again later in life. This is called shingles.
- Trial name
- ZEST (NCT07443709)
- Testing
- Booster dose of the recombinant zoster vaccine (RZV, Shingrix®)
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- Oriol Manuel
Hiv
HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
The primary objective of this study is to determine if an HIV-infected donor liver (HIVD+) transplant is safe with regards to major transplant-related and HIV-related complications
- Trial name
- NCT03734393
- Testing
- HIVD+/R+
- Where
- 26 sites in United States
- Volunteers
- 80 people
- Sponsor
- Johns Hopkins University
Lymphoma, Infection
Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)
The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients.
- Conditions
- Lymphoma, Infection, Leukemia
- Trial name
- NCT00075803
- Testing
- Fluconazole, Voriconazole
- Where
- 33 sites in United States
- Volunteers
- 600 people
- Sponsor
- Medical College of Wisconsin
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
RATIONALE: Reducing the amount of drugs used to prevent transplant rejection may help a person's body kill tumor cells. Giving biological therapy, such as interferon alfa, which may interfere with the growth of cancer cells, or…
- Trial name
- NCT00002657
- Testing
- bleomycin sulfate, recombinant interferon alfa, cyclophosphamide
- Where
- 86 sites in United States
- Volunteers
- 20 people
- Sponsor
- SWOG Cancer Research Network
Infection Due to Resistant Organism
FMT for MDRO Colonization in Solid Organ Transplant
This is a pilot feasibility study to determine whether fecal microbiota transplantation (FMT) can suppress or reverse gastrointestinal carriage of MDROs in hospitalized solid organ transplant recipients with a history of one or…
- Trial name
- FMT (NCT02816437)
- Testing
- OpenBiome Fecal Microbiota Transplantation retention enema
- Sponsor
- University of Miami
Prostate Cancer, Renal Transplantation
Prostate Cancer in Renal Transplants Recipients
Kidney transplantation is considered the standard of care for patients with end-stage kidney disease under chronic dialysis treatment.
- Conditions
- Prostate Cancer, Renal Transplantation, Kidney Transplant Recipients
- Trial name
- RENPRO (NCT04642833)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Florence
Immunization; Infection, Transplantation Infection
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV).
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza
- Trial name
- PSOT (NCT05947071)
- Testing
- Standard Dose Quadrivalent Inactivated Influenza Vaccine, High Dose Quadrivalent Inactivated Influenza Vaccine
- Where
- 11 sites in United States
- Volunteers
- 312 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis E
Seroprevalence of Hepatitis E in People With an Organ Transplant
Background: The hepatitis E virus causes an acute hepatitis that usually goes away by itself. Researchers in France studied people who received a liver or kidney transplant.
- Trial name
- NCT02190253
- Where
- 3 sites in United States
- Volunteers
- 447 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Immunity, Cellular
Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients
The study will prospectively determine the clinical utility of non-pathogen specific cellular immunity assessment using the Quantiferon-Monitor to quantify the degree of immunosuppression.
- Trial name
- QTF-Monitor (NCT02560857)
- Testing
- Quantiferon-Monitor assay
- Where
- Canada
- Volunteers
- 151 people
- Sponsor
- Deepali Kumar
Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
The primary objective of this protocol is to provide expanded access to tabelecleucel to participants with Epstein-Barr virus-associated diseases and malignancies for whom there are no other appropriate therapeutic options, and…
- Conditions
- Epstein-Barr Virus (EBV) Infections, Lymphoproliferative Disorders, EBV+ Associated Lymphoma, EBV+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Trial name
- NCT02822495
- Testing
- tabelecleucel
- Sponsor
- Atara Biotherapeutics
Primary T-cell Immunodeficiency Disorders, Common Variable Immunodeficiency
Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide
Background: People who have certain immune system diseases often need a procedure called allo HSCT. This is short for allogeneic hematopoietic stem cell transplant. This might cure people with these diseases.
- Trial name
- NCT03188419
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- National Cancer Institute (NCI)
Cytomegalovirus Infections
Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients
The purpose of this research study is to investigate whether or not maribavir is safe and effective for preventing CMV disease when taken by mouth for up to 12 weeks in patients who have had a stem cell transplant.
- Trial name
- NCT00411645
- Testing
- maribavir
- Where
- 97 sites in United States, Belgium and 7 more
- Volunteers
- 681 people
- Sponsor
- Shire
Recipient of Kidney Transplant
Kidney Disease and Ultrasound Imaging
The hypothesis of our study is that a correlation exists between the couple ultrasound elastography- renal perfusion estimated with contrast-enhanced ultrasound and the degree of fibrosis estimated in a semi-quantitative way in 4…
- Trial name
- Imag-NCT (NCT02201537)
- Testing
- renal echography
- Where
- France
- Volunteers
- 141 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection
18F-Fluciclovine PET/CT in the Assessment of Pancreatic Transplants
Hypothesis 1: 18F-Fluciclovine PET/CT can correctly and easily identify the pancreatic allograft and determine its viability Aim 1: Assess whether 18F-Fluciclovine can identify the pancreatic allograft accurately and assess its…
- Trial name
- NCT04852523
- Testing
- 18F-fluciclovine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Utah
Kidney Transplantation
A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients
An open-label study to assess the safety, tolerability, and efficacy of FCR001 cell therapy in adult recipients 3-12 months after kidney transplantation from a living donor.
- Trial name
- FREEDOM-2 (NCT01649388)
- Testing
- FCR001
- Where
- 3 sites in United States
- Sponsor
- Talaris Therapeutics Inc.